Host genetic polymorphisms associated with innate immune factors and HIV-1

Current Opinion in HIV and AIDS

Volumn 6, Issue 5, 2011, Pages 427-434

  Sobieszczyk, Magdalena E ^a   Lingappa, Jairam R ^b,d   McElrath, M Juliana ^b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

disease pathogenesis; innate immunity; polymorphism

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERFERON REGULATORY FACTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

DISEASE COURSE; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; INNATE IMMUNITY; KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SEROCONVERSION; SINGLE NUCLEOTIDE POLYMORPHISM;

CARRIER PROTEINS; CYTOKINES; CYTOSINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-3; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTORS;

EID: 80051799415     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283497155     Document Type: Review

References (82)

1. The International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
2. Pine SO, McElrath MJ, Bochud P-Y. Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 2009; 23:2387-2395.
3. Bochud PY, Hersberger M, Taffe P, et al. Polymorphisms in toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21:441-446.
4. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, et al. Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 2008; 49:128-135.
5. Oh DY, Baumann K, Hamouda O, et al. A frequent functional Toll-like receptor polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009; 23:297-307.
6. Nakayama EE, Hoshino Y, Xin X, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype. J Virol 2000; 74:5452-5459. (Pubitemid 30346576)
7. Wichukchinda N, Nakayama EE, Rojanawiwat A, et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 2006; 20:189-196.
8. Soriano A, Lozano F, Oliva H, et al. Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics 2005; 57:644-654. (Pubitemid 41457486)
9. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97:14467-14472. (Pubitemid 32016599)
10. An P, Vlahov D, Margolick JB, et al. A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals. J Infect Dis 2003; 188:228-231. (Pubitemid 36898154)
11. Forthal DN, Landucci G, Bream J, et al. FcgRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179:7916-7923.
12. Javanbakt H, An P, Gold B, et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006; 354:15-27. (Pubitemid 44468115)
13. Nakajima T, Nakayama EE, Kaur G, et al. Impact of novel TRIM5alpha variants, Gly110Arg and G176del, on the anti-HIV-1 activity and the susceptibility to HIV-1 infection. AIDS 2009; 23:2091-2100.
14. Mangano A, Rocco C, Marino SM, et al. Detrimental effects of mannosebinding lectin (MBL2) promoter genotype XA/XA on HIV-1 vertical transmission and AIDS progression. J Infect Dis 2008; 198:694-700.
15. Catano G, Agan BK, Kulkarni H, et al. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations. J Infect Dis 2008; 198:72-80. (Pubitemid 351920292)
16. Baroncelli S, Ricci E, Andreotti M, et al. Single-nucleotide polymorphisms in human beta-defensin-1 gene in Mozambican HIV-1-infected women and correlation with virologic parameters. AIDS 2008; 22:1515-1517.
17. Ricci E, Malacrida S, Zanchetta M, et al. Role of beta-defensin-1 polymorphisms in mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2009; 51:13-19.
18. Martin MP, Lederman MM, Hutcheson HB, et al. Association of DC-SIGN promoter polymorphism with increased risk for parenteral, but not mucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004; 78:14053-14056. (Pubitemid 39612803)
19. Wichukchinda N, Kitamura Y, Rojanawiwat A, et al. The polymorphisms in DCSIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retroviruses 2007; 23:686-692. (Pubitemid 46867466)
20. Zhang J, Zhang X, Fu J, et al. Protective role of DC-SIGN (CD209) neckregion alleles with (Pubitemid 351920291)
21. Fellay J, Ge D, Shianna KV, et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
22. Martinelli E, Cicala C, Van Ryk D, et al. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2007; 104:3396-3401. (Pubitemid 46364170)
23. Heil F, Ahmad-Nejad P, Hemmi H, et al. The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33:2987-2997. (Pubitemid 37428331)
24. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008; 14:86-92. (Pubitemid 351624472)
25. Biasin M, Piacentini L, Lo Caputo S, et al. TLR activation pathways in HIV-1-exposed seronegative individuals. J Immunol 2010; 184:2710-2717.
26. Oh DY, Taube S, Hamouda O, et al. A functional Toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis 2008; 198:701-709.
27. Jiang W, Lederman MM, Mohner RJ, et al. Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008; 82:7837-7845.
28. Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006; 103:177-182. (Pubitemid 43076124)
29. Dalmasso C, Carpentier W, Meyer L, et al. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One 2008; 3:e3907.
30. Le Clerc S, Limou S, Coulonges C, et al. Genome wide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genome wide Association Study 03). J Infect Dis 2009; 200:1194-1201.
31. Le Clerc S, Coulonges C, Delaneau O, et al. Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS. J Acquir Immune Defic Syndr 2011; 56:279-284.
32. Fellay J, Shianna KV, Telenti A, et al. Host genetics and HIV-1: the final phase? PLoS Pathog 2010; 6:e1001033.
33. An P, Winkler CA. Host genes associated with HIV/AIDS: advances in gene discovery. Trends Genet 2010; 3:119-131.
34. Doehle BP, Hladik F, McNevin JP, et al. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J Virol 2009; 83:10395-10405.
35. Rotger M, Dang KK, Fellay J, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog 2010; 6:e1000781.
36. Chakrabarti LA, Simon V. Immune mechanisms of HIV control. Curr Opin Immunol 2010; 22:488-496.
37. Thielen BK, McNevin JP, McElrath MJ, et al. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem 2010; 285:27753-27766.
38. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009; 364:675-687.
39. An P, Bleiber G, Duggal P, et al. APOBEC3G genetic variants and their influence on progression to AIDS. J Virol 2004; 78:11070-11076. (Pubitemid 39299647)
40. Do H, Vasilescu A, Diop G, et al. Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J Infect Dis 2005; 191:159-163. (Pubitemid 40096372)
41. Reddy K, Winkler CA, Werner L, et al. APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS 2010; 24:195-204.
42. Jin X, Wu H, Smith H. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 2007; 4:20.
43. Pace C, Keller J, Nolan D, et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 2006; 80:9259-9269. (Pubitemid 44359998)
44. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, et al. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 2009; 6:23.
45. Jin X, Brooks A, Chen H, et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005; 79:11513-11516. (Pubitemid 41170693)
46. Harari A, Ooms M, Mulder LC, Simon V. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol 2009; 83:295-303.
47. Zhen A, Wang T, Zhao K, et al. Single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol 2010; 84:1902-1911.
48. Nathans R, Cao H, Sharova N, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 2008; 26:1187-1192.
49. Albin JS, Harris RS. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med 2010; 12:e4.
50. Wu X, Anderson JL, Campbell EM, et al. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci USA 2006; 103:7465-7470. (Pubitemid 43727856)
51. Sewram S, Singh R, Kormuth E, et al. Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J Infect Dis 2009; 199:1657-1663.
52. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9:503-510. (Pubitemid 351560519)
53. Carrington M, Martin MP, van Bergen J. KIR-HLA intercourse in HIV disease. Trends Microbiol 2008; 16:620-627.
54. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005; 5:835-843. (Pubitemid 41581665)
55. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010; 129:8-19.
56. Bashirova AA, Thomas R, Carrington M. HLA/KIR restraint of HIV: surviving the fittest. Annu Rev Immunol 2011; 29:295-317.
57. Paximadis M, Minevich G, Winchester R, et al. KIR-HLA and maternal-infant HIV-1 transmission in sub-Saharan Africa. PLoS One 2011; 6:e16541.
58. Jennes W, Verheyden S, Demanet C, et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006; 177:6588-6592. (Pubitemid 44715020)
59. Merino A, Malhotra R, Morton M, et al. Impact of a functional KIR2DS4 allele on heterosexual HIV-1 transmission among discordant Zambian couples. J Infect Dis 2011; 203:487-495.
60. Gaudieri S, DeSantis D, McKinnonet E, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005; 6:683-690. (Pubitemid 41741713)
61. Martin MP, Gao X, Lee JH, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434. (Pubitemid 35154456)
62. Alter G, Rihn S, Walter K, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009; 83:6798-6805.
63. Barbour JD, Sriram U, Caillier SJ, et al. Synergy or independence? Deciphering the interaction of HLA class I and NK cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 2007; 3:e43.
64. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740. (Pubitemid 46848586)
65. Boulet S, Kleyman M, Kim JY, et al. A combined genotype of KIR3DL1 high expressing alleles and HLA-B57 is associated with a reduced risk of HIV infection. AIDS 2008; 22:1487-1491.
66. Boulet S, Song R, Kamya P, et al. HIV protective KIR3DL1 and HLAB genotypes influence NK cell function following stimulation with HLA-devoid cells. J Immunol 2010; 184:2057-2064.
67. Berger CT, Alter G. Natural killer cells in spontaneous control of HIV infection. Curr Opin HIV AIDS 2011; 6:208-213.
68. Qi Y, Martin MP, Gao P, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2006; 2:e79.
69. Anfossi N, Andre P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-342. (Pubitemid 44224147)
70. Alter G, Altfeld M. NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009; 265:29-42.
71. Thomas R, Yamada E, Alter G, et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol 2008; 180:6743-6750.
72. Kim S, Sunwoo JB, Yang L, et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA 2008; 105:3053-3058. (Pubitemid 351723666)
73. Alter G, Martin MP, Teigen N, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027-3036. (Pubitemid 350179568)
74. Long BR, Ndhlovu LC, Oksenberg JR, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008; 82:4785-4792. (Pubitemid 351657040)
75. Scott-Algara D, Truong LX, Versmisse P, et al. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J Immunol 2003; 171:5663-5667. (Pubitemid 37467178)
76. Ravet S, Scott-Algara D, Bonnet E, et al. Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 2007; 109:4296-4305. (Pubitemid 46743396)
77. Jennes W, Verheyden S, Demanet C, et al. Low CD4+ T cell counts among African HIV-1 infected subjects with group B KIR haplotypes in the absence of specific inhibitory KIR ligands. PLoS One 2011; 6:e17043.
78. Van Manen D, Kootstra NA, Boeser-Nunnink B, et al. Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS 2009; 23:19-28.
79. Thomas R, Apps R, Qi Y, et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-1294.
80. Onyango CO, Leligdowicz A, Yokoyama M, et al. HIV-2 capsids distinguish high and low virus load patients in a West African community cohort. Vaccine 2010; S2:B60-B67.
81. Nowroozalizadeh S, Mansson F, da Silva Z, et al. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infection. Cytokine 2009; 46:325-331.
82. Yindom L-M, Leligdowicz A, Martin MP, et al. Influence of HLA class I and HLA-KIR compound genotypes on HIV-2 infection and markers of disease progression in a Manjako Community in West Africa. J Virol 2010; 84:8202-8208.